Objective:
high-grade glioma
*Zhuang Kang and Shan Li contributed equally to this work.This study was aimed at analyzing the efficacy and safety of an injectable form of chlorogenic acid (CGA) in patients with recurrent high-grade glioma after standard of care treatments, through a first-in-human, open-label, dose-escalation phase I trial.